Lopez, I am not having a go at you or presuming anyone else is...

Lopez,

I am not having a go at you or presuming anyone else is having a go at me. You put the point to me, even though I never contended your assertion, and I answered somewhat politely and ambivalently, despite your comments an unimportant aside. Stop gaslighting.

Again, its two clinically and professional informed additions to the board that that will prove very useful internationally recognised orthopaedic surgeons, who specialise in nerve transfer and peripheral nerve repair and are involved in the Medical Scientific Advisory Board, out of two leading US academic research institutions and hospitals, heavily involved and specifically recruited to assist with clinical development and US market access for REmplir

Price sensitive at the ASX or not, who cares? it should arguably be, in that it improves OCC's pathway to commercial success for Remplir in the US.

Its simply good news and the addition inarguably improves both the Board and the company's business prospects.